Cargando…

Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma

Glioblastoma (GBM) is a highly aggressive tumor of the brain. Despite the efforts, response to current therapies is poor and 2-years survival rate ranging from 6-12%. Here, we evaluated the preclinical efficacy of Metformin (MET) as add-on therapy to Temozolomide (TMZ) and the ability of [(18)F]FLT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valtorta, Silvia, Lo Dico, Alessia, Raccagni, Isabella, Martelli, Cristina, Pieri, Valentina, Rainone, Paolo, Todde, Sergio, Zinnhardt, Bastian, De Bernardi, Elisabetta, Coliva, Angela, Politi, Letterio S., Viel, Thomas, Jacobs, Andreas H., Galli, Rossella, Ottobrini, Luisa, Vaira, Valentina, Moresco, Rosa Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126706/ https://www.ncbi.nlm.nih.gov/pubmed/34012924 http://dx.doi.org/10.3389/fonc.2021.664149

Ejemplares similares

Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models
por: Valtorta, Silvia, et al.
Publicado: (2017)

Role of Metformin and AKT Axis Modulation in the Reversion of Hypoxia Induced TMZ-Resistance in Glioma Cells
por: Lo Dico, Alessia, et al.
Publicado: (2019)

Effects of Metformin as Add-On Therapy against Glioblastoma: An Old Medicine for Novel Oncology Therapeutics
por: Guarnaccia, Laura, et al.
Publicado: (2022)

Evaluating [(18)F]FDG and [(18)F]FLT Radiotracers as Biomarkers of Response for Combined Therapy Outcome in Triple-Negative and Estrogen-Receptor-Positive Breast Cancer Models
por: Rainone, Paolo, et al.
Publicado: (2023)

Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-Angiogenic Add-On Therapy in Glioblastoma
por: Guarnaccia, Laura, et al.
Publicado: (2021)

Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates
por: Bertoli, Gloria, et al.
Publicado: (2021)

The Multifaceted Role of CMA in Glioma: Enemy or Ally?
por: Lo Dico, Alessia, et al.
Publicado: (2021)

Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance
por: Valtorta, Silvia, et al.
Publicado: (2020)

Optical imaging probes in oncology
por: Martelli, Cristina, et al.
Publicado: (2016)

Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide
por: Lo Dico, Alessia, et al.
Publicado: (2018)

CMA mediates resistance in breast cancer models
por: Lo Dico, Alessia, et al.
Publicado: (2023)

Intracellular Redox-Balance Involvement in Temozolomide Resistance-Related Molecular Mechanisms in Glioblastoma
por: Lo Dico, Alessia, et al.
Publicado: (2019)

A stapled chromogranin A-derived peptide homes in on tumors that express αvβ6 or αvβ8 integrins
por: Monieri, Matteo, et al.
Publicado: (2023)

Theranostic application of miR-429 in HER2+ breast cancer
por: Cava, Claudia, et al.
Publicado: (2020)

Study of the Tissue Distribution of TLQP-21 in Mice Using [(18)F]JMV5763, a Radiolabeled Analog Prepared via [(18)F]Aluminum Fluoride Chelation Chemistry
por: Turolla, Elia A., et al.
Publicado: (2018)

Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy
por: Rainone, Veronica, et al.
Publicado: (2016)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Radiosynthesis and Preclinical Evaluation of (11)C-VA426, a Cyclooxygenase-2 Selective Ligand
por: Carpinelli, Assunta, et al.
Publicado: (2019)

[(18)F]FDG and [(18)F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer
por: Raccagni, Isabella, et al.
Publicado: (2018)

Lipophilic dye-compatible brain clearing technique allowing correlative magnetic resonance/high-resolution fluorescence imaging in rat models of glioblastoma
por: Peviani, Marco, et al.
Publicado: (2020)

Imaging temozolomide-induced changes in the myeloid glioma microenvironment
por: Foray, Claudia, et al.
Publicado: (2021)

Translation Imaging in Parkinson’s Disease: Focus on Neuroinflammation
por: Belloli, Sara, et al.
Publicado: (2020)

Correction: Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy
por: Rainone, Veronica, et al.
Publicado: (2016)

Specific V-ATPase expression sub-classifies IDHwt lower-grade gliomas and impacts glioma growth in vivo
por: Terrasi, Andrea, et al.
Publicado: (2019)

Inhibition of the Hexosamine Biosynthetic Pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis
por: Ricciardiello, Francesca, et al.
Publicado: (2018)

What’s next after metformin? focus on sulphonylurea: add-on or combination therapy
por: Lim, Phei C., et al.
Publicado: (2015)

Trends in add-on medications following metformin monotherapy for type 2 diabetes
por: Swart, Elizabeth CS, et al.
Publicado: (2022)

(18)F-VC701-PET and MRI in the in vivo neuroinflammation assessment of a mouse model of multiple sclerosis
por: Belloli, Sara, et al.
Publicado: (2018)

MiR675-5p Acts on HIF-1α to Sustain Hypoxic Responses: A New Therapeutic Strategy for Glioma
por: Lo Dico, Alessia, et al.
Publicado: (2016)

The Radiology Department during the COVID-19 pandemic: a challenging, radical change
por: Politi, Letterio S., et al.
Publicado: (2020)

Exploring the neuroprotective effects of montelukast on brain inflammation and metabolism in a rat model of quinolinic acid-induced striatal neurotoxicity
por: Tassan Mazzocco, Margherita, et al.
Publicado: (2023)

[(18)F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma
por: Valtorta, Silvia, et al.
Publicado: (2021)

A GBM-like V-ATPase signature directs cell-cell tumor signaling and reprogramming via large oncosomes
por: Bertolini, Irene, et al.
Publicado: (2019)

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
por: Odawara, Masato, et al.
Publicado: (2014)

Placental Antioxidant Defenses and Autophagy-Related Genes in Maternal Obesity and Gestational Diabetes Mellitus
por: Diceglie, Cecilia, et al.
Publicado: (2021)

Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study
por: Roberto, Giuseppe, et al.
Publicado: (2022)

Editorial: Untangling post-treatment follow up of brain tumors: the role of neuroimaging
por: Anzalone, Nicoletta, et al.
Publicado: (2023)

Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder
por: Hebrani, Paria, et al.
Publicado: (2015)

ODP173 Control of Alpelisib-Induced Hyperglycemia With DPP4- Inhibitors as add on to Metformin and Insulin
por: Hee, Nicholas Ken Yoong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0jigvruc2dij0fbho3ghh0ml9a